(MIRM) Mirum Pharmaceuticals - Ratings and Ratios
LIVMARLI, Cholbam, Chenodal, Volixibat
MIRM EPS (Earnings per Share)
MIRM Revenue
Description: MIRM Mirum Pharmaceuticals
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) is a biopharmaceutical company specializing in developing and commercializing novel therapies for rare and orphan diseases. The companys lead product, LIVMARLI, is an orally administered IBAT inhibitor approved for treating cholestatic pruritus in Alagille syndrome patients. With a portfolio of approved and investigational treatments, Mirum is focused on addressing significant unmet medical needs.
Key performance indicators (KPIs) for Mirum Pharmaceuticals include revenue growth from its approved products, LIVMARLI, Cholbam, and Chenodal. The companys ability to successfully commercialize these treatments and advance its pipeline, including Volixibat, will be crucial in driving future growth. With a market capitalization of approximately $2.58 billion, Mirums financial performance and ability to invest in research and development will be closely watched. The companys return on equity (ROE) is currently negative, indicating significant investment in growth initiatives.
The companys pipeline and commercial products are focused on rare and orphan diseases, including cholestatic liver diseases and cerebrotendinous xanthomatosis. The success of LIVMARLI and the progression of Volixibat through clinical trials will be important drivers of the companys growth prospects. As a biotechnology company, Mirums valuation is sensitive to developments in its pipeline and the competitive landscape.
From a financial perspective, Mirum Pharmaceuticals has a forward price-to-earnings (P/E) ratio of 39.68, indicating a significant premium to its earnings. This is not unusual for a growth-stage biotechnology company with a promising pipeline. Investors will be monitoring the companys ability to deliver on its growth prospects and manage its financial resources effectively.
MIRM Stock Overview
| Market Cap in USD | 3,818m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2019-07-18 |
MIRM Stock Ratings
| Growth Rating | 90.8% |
| Fundamental | 43.8% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 53.2% |
| Analyst Rating | 4.60 of 5 |
MIRM Dividends
Currently no dividends paidMIRM Growth Ratios
| Growth Correlation 3m | 91.4% |
| Growth Correlation 12m | 76% |
| Growth Correlation 5y | 90% |
| CAGR 5y | 50.04% |
| CAGR/Max DD 3y | 1.54 |
| CAGR/Mean DD 3y | 5.17 |
| Sharpe Ratio 12m | 0.45 |
| Alpha | 0.18 |
| Beta | 0.443 |
| Volatility | 44.40% |
| Current Volume | 607k |
| Average Volume 20d | 604.1k |
| Stop Loss | 70 (-4.3%) |
| Signal | 0.12 |
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (-58.6m TTM) > 0 and > 6% of Revenue (6% = 25.7m TTM) |
| FCFTA 0.01 (>2.0%) and ΔFCFTA 15.07pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 71.91% (prev 96.65%; Δ -24.74pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.01 (>3.0%) and CFO 8.99m > Net Income -58.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.13 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (49.7m) change vs 12m ago 5.28% (target <= -2.0% for YES) |
| Gross Margin 79.02% (prev 73.19%; Δ 5.84pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 61.90% (prev 40.01%; Δ 21.89pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -3.00 (EBITDA TTM -18.8m / Interest Expense TTM 14.3m) >= 6 (WARN >= 3) |
Altman Z'' -2.10
| (A) 0.43 = (Total Current Assets 453.4m - Total Current Liabilities 144.8m) / Total Assets 725.8m |
| (B) -0.92 = Retained Earnings (Balance) -664.7m / Total Assets 725.8m |
| (C) -0.06 = EBIT TTM -43.0m / Avg Total Assets 693.3m |
| (D) -1.41 = Book Value of Equity -664.4m / Total Liabilities 470.7m |
| Total Rating: -2.10 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 43.75
| 1. Piotroski 2.50pt = -2.50 |
| 2. FCF Yield 0.24% = 0.12 |
| 3. FCF Margin 2.17% = 0.54 |
| 4. Debt/Equity 1.22 = 1.80 |
| 5. Debt/Ebitda -16.55 = -2.50 |
| 6. ROIC - WACC (= -15.04)% = -12.50 |
| 7. RoE -24.76% = -2.50 |
| 8. Rev. Trend 98.06% = 7.35 |
| 9. EPS Trend 78.51% = 3.93 |
What is the price of MIRM shares?
Over the past week, the price has changed by -2.33%, over one month by +9.69%, over three months by +44.26% and over the past year by +81.53%.
Is Mirum Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MIRM is around 98.47 USD . This means that MIRM is currently undervalued and has a potential upside of +34.63% (Margin of Safety).
Is MIRM a buy, sell or hold?
- Strong Buy: 6
- Buy: 4
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the MIRM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 77.2 | 5.6% |
| Analysts Target Price | 77.2 | 5.6% |
| ValueRay Target Price | 108.4 | 48.2% |
Last update: 2025-09-13 05:03
MIRM Fundamental Data Overview
CCE Cash And Equivalents = 304.6m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 39.6825
P/S = 8.8954
P/B = 14.744
Beta = 0.927
Revenue TTM = 429.2m USD
EBIT TTM = -43.0m USD
EBITDA TTM = -18.8m USD
Long Term Debt = 308.9m USD (from longTermDebt, last quarter)
Short Term Debt = 2.08m USD (from shortTermDebt, last quarter)
Debt = 311.0m USD (Calculated: Short Term 2.08m + Long Term 308.9m)
Net Debt = 90.8m USD (from netDebt column, last quarter)
Enterprise Value = 3.82b USD (3.82b + Debt 311.0m - CCE 304.6m)
Interest Coverage Ratio = -3.00 (Ebit TTM -43.0m / Interest Expense TTM 14.3m)
FCF Yield = 0.24% (FCF TTM 9.33m / Enterprise Value 3.82b)
FCF Margin = 2.17% (FCF TTM 9.33m / Revenue TTM 429.2m)
Net Margin = -13.65% (Net Income TTM -58.6m / Revenue TTM 429.2m)
Gross Margin = 79.02% ((Revenue TTM 429.2m - Cost of Revenue TTM 90.0m) / Revenue TTM)
Tobins Q-Ratio = -5.76 (set to none) (Enterprise Value 3.82b / Book Value Of Equity -664.4m)
Interest Expense / Debt = 1.15% (Interest Expense 3.59m / Debt 311.0m)
Taxrate = 21.0% (US default)
NOPAT = -43.0m (EBIT -43.0m, no tax applied on loss)
Current Ratio = 3.13 (Total Current Assets 453.4m / Total Current Liabilities 144.8m)
Debt / Equity = 1.22 (Debt 311.0m / last Quarter total Stockholder Equity 255.2m)
Debt / EBITDA = -16.55 (Net Debt 90.8m / EBITDA -18.8m)
Debt / FCF = 33.33 (Debt 311.0m / FCF TTM 9.33m)
Total Stockholder Equity = 236.5m (last 4 quarters mean)
RoA = -8.07% (Net Income -58.6m, Total Assets 725.8m )
RoE = -24.76% (Net Income TTM -58.6m / Total Stockholder Equity 236.5m)
RoCE = -7.89% (Ebit -43.0m / (Equity 236.5m + L.T.Debt 308.9m))
RoIC = -7.89% (NOPAT -43.0m / Invested Capital 544.8m)
WACC = 7.14% (E(3.82b)/V(4.13b) * Re(7.65%)) + (D(311.0m)/V(4.13b) * Rd(1.15%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 3.26%
Discount Rate = 7.65% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 72.63% ; FCFE base≈9.33m ; Y1≈6.77m ; Y5≈3.78m
Fair Price DCF = 1.43 (DCF Value 72.0m / Shares Outstanding 50.2m; 5y FCF grow -32.40% → 3.0% )
EPS Correlation: 78.51 | EPS CAGR: 26.83% | SUE: 0.49 | # QB: 0
Revenue Correlation: 98.06 | Revenue CAGR: 100.8% | SUE: 3.64 | # QB: 2
Additional Sources for MIRM Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle